There is a developing story that the increased use of testosterone therapy without a diagnosis of hypogonadism is associated with an elevated cardiovascular risk for some patients. In this issue of JAMA Internal Medicine, Layton and coauthors1 deepen our knowledge with their analysis of 3 large databases (Truven MarketScan and Medicare cohorts from the United States and the Clinical Practice Research Datalink cohort from the United Kingdom) to ask whether they could detect a difference in cardiovascular or cerebrovascular events and mortality in patients newly prescribed testosterone therapy in the form of injectable testosterone compared with testosterone gels or patches.
Wierman ME. Risks of Different Testosterone PreparationsToo Much, Too Little, Just Right. JAMA Intern Med. 2015;175(7):1197-1198. doi:10.1001/jamainternmed.2015.1580